degarelix 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
gonadotropin-releasing-hormone (GnRH) inhibitors, peptides 4379 214766-78-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • degarelix
  • firmagon
  • degarelix acetate
FE-200486 is the acetate salt
  • Molecular weight: 1632.29
  • Formula: C82H103ClN18O16
  • CLOGP: -0.74
  • LIPINSKI: 3
  • HAC: 34
  • HDO: 17
  • TPSA: 512.87
  • ALOGS: -5.60
  • ROTB: 41

Drug dosage:

DoseUnitRoute
2.70 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.74 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.68 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 24, 2008 FDA FERRING
June 26, 2012 PMDA Astellas Pharma Inc.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site erythema 340.79 20.57 123 6316 15776 34934716
Injection site pain 314.59 20.57 150 6289 38855 34911637
Injection site swelling 216.57 20.57 81 6358 11446 34939046
Prostatic specific antigen increased 204.41 20.57 83 6356 14597 34935895
Injection site induration 169.28 20.57 48 6391 2812 34947680
Hot flush 162.37 20.57 75 6364 17991 34932501
Osteonecrosis of jaw 132.42 20.57 65 6374 17824 34932668
Injection site mass 100.92 20.57 40 6399 6586 34943906
Injection site nodule 85.11 20.57 25 6414 1658 34948834
Injection site reaction 77.87 20.57 41 6398 12992 34937500
Injection site warmth 67.72 20.57 22 6417 2040 34948452
Injection site cellulitis 64.24 20.57 16 6423 565 34949927
Metastases to bone 64.05 20.57 35 6404 11935 34938557
Prostatic specific antigen abnormal 56.12 20.57 15 6424 703 34949789
Interstitial lung disease 50.27 20.57 61 6378 65221 34885271
Hypocalcaemia 45.72 20.57 37 6402 24252 34926240
Prostate cancer metastatic 42.64 20.57 21 6418 5782 34944710
Necrotising retinitis 40.35 20.57 12 6427 830 34949662
Injection site abscess 40.25 20.57 12 6427 837 34949655
Injection site inflammation 39.33 20.57 12 6427 906 34949586
Malignant neoplasm progression 36.19 20.57 61 6378 87985 34862507
Prescribed underdose 34.15 20.57 21 6418 8912 34941580
Injection site discomfort 32.71 20.57 12 6427 1598 34948894
Blood testosterone abnormal 28.86 20.57 8 6431 430 34950062
Infusion site plaque 27.63 20.57 4 6435 4 34950488
Urethral obstruction 24.48 20.57 6 6433 198 34950294
Blood testosterone increased 24.07 20.57 9 6430 1264 34949228
Metastases to spine 24.03 20.57 11 6428 2573 34947919
Toxic cataract 23.24 20.57 4 6435 20 34950472
Hepatic function abnormal 22.70 20.57 34 6405 44329 34906163
Metastases to liver 21.95 20.57 19 6420 13644 34936848
Mucocutaneous disorder 21.66 20.57 5 6434 127 34950365
Product lot number issue 21.51 20.57 4 6435 33 34950459
Drug ineffective 21.41 20.57 32 6407 456719 34493773
Decreased appetite 21.14 20.57 73 6366 166319 34784173
Hormone-refractory prostate cancer 20.71 20.57 7 6432 733 34949759
Prostatic specific antigen decreased 20.67 20.57 5 6434 156 34950336

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 236.40 21.75 66 5208 10320 79728794
Injection site erythema 184.53 21.75 94 5180 78103 79661011
Injection site pain 177.53 21.75 109 5165 129729 79609385
Osteonecrosis of jaw 135.05 21.75 63 5211 43163 79695951
Injection site swelling 126.84 21.75 62 5212 47070 79692044
Injection site induration 117.42 21.75 38 5236 9781 79729333
Hot flush 109.44 21.75 59 5215 54818 79684296
Injection site mass 74.28 21.75 33 5241 20151 79718963
Injection site nodule 63.57 21.75 19 5255 3761 79735353
Interstitial lung disease 58.66 21.75 53 5221 112547 79626567
Injection site cellulitis 53.85 21.75 14 5260 1664 79737450
Hypocalcaemia 51.03 21.75 35 5239 49889 79689225
Prostate cancer metastatic 49.90 21.75 16 5258 3991 79735123
Necrotising retinitis 47.88 21.75 12 5262 1233 79737881
Metastases to bone 45.15 21.75 25 5249 24402 79714712
Injection site abscess 44.60 21.75 12 5262 1628 79737486
Prostatic specific antigen abnormal 42.23 21.75 9 5265 452 79738662
Prostate cancer 38.01 21.75 25 5249 33243 79705871
Infusion site plaque 30.83 21.75 4 5270 6 79739108
Malignant neoplasm progression 30.29 21.75 41 5233 135949 79603165
Injection site warmth 29.70 21.75 16 5258 14791 79724323
Prostatic specific antigen decreased 29.39 21.75 5 5269 73 79739041
Urethral obstruction 28.71 21.75 6 5268 274 79738840
Decreased appetite 28.51 21.75 67 5207 342351 79396763
Hepatic function abnormal 27.84 21.75 29 5245 73078 79666036
Toxic cataract 27.33 21.75 4 5270 20 79739094
Injection site inflammation 26.66 21.75 10 5264 3966 79735148
Prescribed underdose 26.22 21.75 19 5255 29495 79709619
Mucocutaneous disorder 26.13 21.75 5 5269 145 79738969
Metastases to spine 25.84 21.75 10 5264 4314 79734800
Hormone-refractory prostate cancer 25.74 21.75 6 5268 454 79738660
Blood testosterone increased 25.35 21.75 7 5267 1045 79738069
Urinary retention 24.37 21.75 24 5250 56606 79682508
Retinal detachment 24.34 21.75 12 5262 9235 79729879
Injection site reaction 23.17 21.75 23 5251 54762 79684352

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Other hormone antagonists and related agents
FDA PE N0000008638 Decreased GnRH Secretion
FDA MoA N0000175084 Gonadotropin Releasing Hormone Receptor Antagonists
FDA EPC N0000175839 Gonadotropin Releasing Hormone Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Advanced Prostatic Carcinoma indication
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.99 acidic
pKa2 11.49 acidic
pKa3 12.21 acidic
pKa4 12.25 acidic
pKa5 12.82 acidic
pKa6 13.11 acidic
pKa7 13.11 acidic
pKa8 13.39 acidic
pKa9 13.47 acidic
pKa10 13.85 acidic
pKa11 9.64 Basic
pKa12 5.35 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10729739 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10973870 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9579359 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10729739 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10973870 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9579359 Feb. 10, 2029 TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10695398 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 120MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9415085 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 10695398 April 27, 2032 METHOD OF TREATING PROSTATE CANCER
EQ 80MG BASE/VIAL FIRMAGON FERRING N022201 Dec. 24, 2008 RX POWDER SUBCUTANEOUS 9415085 April 27, 2032 METHOD OF TREATING PROSTATE CANCER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR ANTAGONIST Ki 8.77 IUPHAR CHEMBL

External reference:

IDSource
D08635 KEGG_DRUG
4028567 VUID
N0000178334 NUI
934246-14-7 SECONDARY_CAS_RN
4028567 VANDF
C1455035 UMLSCUI
CHEBI:135961 CHEBI
CHEMBL415606 ChEMBL_ID
CHEMBL2028987 ChEMBL_ID
DB06699 DRUGBANK_ID
C431566 MESH_SUPPLEMENTAL_RECORD_UI
5585 IUPHAR_LIGAND_ID
8192 INN_ID
SX0XJI3A11 UNII
16136245 PUBCHEM_CID
475230 RXNORM
164686 MMSL
168716 MMSL
26319 MMSL
d07411 MMSL
012979 NDDF
012980 NDDF
441758000 SNOMEDCT_US
441864003 SNOMEDCT_US

Pharmaceutical products:

None